Author

S. Dewhurst

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:host-pathogen & immune response· 1 Assay:spatial transcriptomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. C. Lowen· 1 shared A. Cox· 1 shared A. Garcia-Sastre· 1 shared A. Nogales· 1 shared C. S. Anderson· 1 shared D. H. Mathews· 1 shared G. Asantewaa· 1 shared I. S. Harris· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. C. Lowen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Generation and functional analysis of defective viral genomes during SARS-CoV-2 infection

T. Zhou, N. J. Gilliam, S. Li, S. Spaudau, R. Osborn, C. S. Anderson, T. J. Mariani, J. Thakar, S. Dewhurst, D. H. Mathews, L. Huang, Y. Sun

This study identifies DVG generation in SARS-CoV-2 and links it to IFN stimulation and persistent infection, showing higher DVG levels in symptomatic patients.

bioRxiv · Sep 22, 2022Microbiology

A single amino acid substitution in PB1 of pandemic H1N1 with A/Ann Arbor/6/60 master donor virus mutations as a novel live-attenuated influenza virus vaccine

A. Nogales, J. Steel, W.-C. Liu, A. C. Lowen, L. Rodriguez, K. Chiem, A. Cox, A. Garcia-Sastre, R. Albrecht, S. Dewhurst, L. Martinez-Sobrido

This paper shows that a single amino acid change in the PB1 protein of the pandemic H1N1 virus can create a live-attenuated vaccine with reduced pathogenicity and transmission.

bioRxiv · Jan 7, 2022 · PreprintMicrobiology

Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro

M. H. Raymonda, J. H. Ciesla, M. Monaghan, J. Leach, G. Asantewaa, L. A. Smorodintsev-Schiller, M. M. Lutz, X. L. Schafer, T. Takimoto, S. Dewhurst, J. Munger, I. S. Harris

This study identifies lapatinib as a potent antiviral against SARS-CoV-2 in vitro, showing over 50,000-fold inhibition without toxicity.

bioRxiv · Nov 25, 2020Microbiology